Anavex Life Sciences Corp.
AVXL
$4.20
-$0.06-1.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.33% | 24.98% | 17.65% | -1.78% | 0.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.33% | 0.34% | 9.19% | 11.19% | 7.74% |
| Operating Income | 16.33% | -0.34% | -9.19% | -11.19% | -7.74% |
| Income Before Tax | 14.11% | -7.85% | -15.82% | -16.06% | -7.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.08% | -7.85% | -15.99% | -16.13% | -7.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.08% | -7.85% | -15.99% | -16.13% | -7.73% |
| EBIT | 16.33% | -0.34% | -9.19% | -11.19% | -7.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 15.81% | -5.73% | -13.03% | -12.03% | -3.08% |
| Normalized Basic EPS | 15.82% | -5.75% | -12.88% | -11.99% | -5.41% |
| EPS Diluted | 15.81% | -5.73% | -13.03% | -12.03% | -3.08% |
| Normalized Diluted EPS | 15.82% | -5.75% | -12.88% | -11.99% | -5.41% |
| Average Basic Shares Outstanding | 2.61% | 2.18% | 2.72% | 3.61% | 4.14% |
| Average Diluted Shares Outstanding | 2.61% | 2.18% | 2.72% | 3.61% | 4.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |